Let’s start up with the current stock price of Y-mAbs Therapeutics Inc. (YMAB), which is $40.75 to be very precise. The Stock rose vividly during the last session to $46.11 after opening rate of $44.92 while the lowest price it went was recorded $41.92 before closing at $41.98.
Recently in News on February 18, 2021, Y-mAbs Announces Pricing of Public Offering of Common Stock. Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its public offering of 2,439,025 shares of its common stock at a public offering price of $41.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100.0 million. All of the shares are being offered by Y-mAbs. In addition, Y-mAbs has granted the underwriters a 30-day option to purchase up to an additional 365,853 shares of common stock at the public offering price, less the underwriting discounts. The offering is expected to close on February 22, 2021, subject to the satisfaction of customary closing conditions. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Y-mAbs Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $53.18 on 01/12/21, with the lowest value was $40.39 for the same time period, recorded on 02/18/21.
Y-mAbs Therapeutics Inc. (YMAB) full year performance was 27.99%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Y-mAbs Therapeutics Inc. shares are logging -26.20% during the 52-week period from high price, and 187.78% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $14.16 and $55.22.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 403752 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Y-mAbs Therapeutics Inc. (YMAB) recorded performance in the market was -15.21%, having the revenues showcasing -12.65% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.71B, as it employees total of 65 workers.
Analysts verdict on Y-mAbs Therapeutics Inc. (YMAB)
During the last month, 8 analysts gave the Y-mAbs Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 46.06, with a change in the price was noted +4.22. In a similar fashion, Y-mAbs Therapeutics Inc. posted a movement of +11.50% for the period of last 100 days, recording 205,071 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for YMAB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Y-mAbs Therapeutics Inc. (YMAB): Technical Analysis
Raw Stochastic average of Y-mAbs Therapeutics Inc. in the period of last 50 days is set at 3.56%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 5.04%. In the last 20 days, the company’s Stochastic %K was 23.11% and its Stochastic %D was recorded 46.81%.
Let’s take a glance in the erstwhile performances of Y-mAbs Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -15.21%. Additionally, trading for the stock in the period of the last six months notably improved by 1.67%, alongside a boost of 27.99% for the period of the last 12 months. The shares increased approximately by -11.62% in the 7-day charts and went up by -11.71% in the period of the last 30 days. Common stock shares were lifted by -12.65% during last recorded quarter.